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Abstract
Background: Critical to the development of new drugs for treatment of malaria is the capacity to safely evaluate their
activity in human subjects. The approach that has been most commonly used is testing in subjects with natural malaria
infection, a methodology that may expose symptomatic subjects to the risk of ineffective treatment. Here we describe the
development and pilot testing of a system to undertake experimental infection using blood stage Plasmodium falciparum
parasites (BSP). The objectives of the study were to assess the feasibility and safety of induced BSP infection as a method for
assessment of efficacy of new drug candidates for the treatment of P. falciparum infection.
Methods and Findings: A prospective, unblinded, Phase IIa trial was undertaken in 19 healthy, malaria-naı¨ve, male adult
volunteers who were infected with BSP and followed with careful clinical and laboratory observation, including a sensitive,
quantitative malaria PCR assay. Volunteers were randomly allocated to treatment with either of two licensed antimalarial
drug combinations, artemether–lumefantrine (A/L) or atovaquone-proguanil (A/P). In the first cohort (n = 6) where
volunteers received ,360 BSP, none reached the target parasitemia of 1,000 before the day designated for antimalarial
treatment (day 6). In the second and third cohorts, 13 volunteers received 1,800 BSP, with all reaching the target parasitemia
before receiving treatment (A/L, n = 6; A/P, n = 7) The study demonstrated safety in the 19 volunteers tested, and a
significant difference in the clearance kinetics of parasitemia between the drugs in the 13 evaluable subjects, with mean
parasite reduction ratios of 759 for A/L and 17 for A/P (95% CI 120–4786 and 7–40 respectively; p,0.01).
Conclusions: This system offers a flexible and safe approach to testing the in vivo activity of novel antimalarials.
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Introduction
Significant advances have been made recently in the control of
malaria [1,2], with reductions in the incidence and prevalence of
infection as well as in malaria-associated mortality. Despite this,
half of the world’s population remains at risk of infection, with an
estimated 225 million cases occurring in 2009, resulting in an
estimated 781,000 deaths [2]. While the reduction in burden of
malaria is likely to be due to multiple factors, including the
increasing use of insecticide-treated bed nets, the replacement of
ineffective antimalarials with artemisinin combination therapy
(ACT) has been recognized as a major factor in reducing the
burden of malaria [2]. However, the most deadly species of
malarial parasites, Plasmodium falciparum, has successfully developed
resistance to almost every antimalarial drug currently marketed.
The concerning reports of slow clearance of P. falciparum
parasitemia following artemisinin therapy in southeast Asia [3]
reinforce the requirement to develop new antimalarials to replace
drugs losing their efficacy [4]. Additional reasons for the
development of new antimalarials include the need to substitute
drugs with unfavourable pharmacokinetic or toxicology profiles,
and to develop drugs that can be given safely to pregnant women
and young children.
Over the last decade there has been a concerted effort to
discover and develop new antimalarial agents [5]. At the
development end of the pipeline, new fixed-dose artemisinin-
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based combination therapies (ACTs) are nearing approval, and
synthetic alternatives to artemisinins, potentially able to treat
emerging resistant strains are in early stages of clinical develop-
ment (ClinicalTrials.gov Identifier: NCT01213966). On the
discovery stage, screening of several million compounds has
resulted in the identification of thousands of new leads with
antimalarial activity, allowing optimization and selection of new
agents with new mechanisms of action [6,7,8].
The selection of the most promising new agents for formal
development necessitates the assessment of their safety and efficacy
via extensive in vitro and animal testing, followed by Phase I safety
and pharmacokinetic studies in healthy human volunteers,
followed by Phase II clinical studies to establish an effective dose
and regimen. However, it is not possible to predict with confidence
the effective starting doses in patients based on in vitro and animal
testing. Therefore, the initial Phase II studies in humans must be
carefully designed to safeguard the patient in the event of an
ineffective dose, while allowing enough time to observe the effect
of the agent.
The predominant method for gathering preliminary efficacy
data for candidate antimalarials has been to undertake trials in
malaria-endemic areas with individuals with patent parasitemia
[9,10]. Such approaches are hindered by a number of factors,
including the effect of clinical immunity [11], and the ethical and
logistical problems of using a drug of unproven efficacy in subjects
with clinical illness who could quickly develop to severe disease.
Although trials in asymptomatic, parasitaemic subjects are safer
than those in symptomatic patients, the results of such trials in
clinically immune subjects may not be predictive of a drug’s
efficacy in non-immune subjects. Further, the fall in malaria
transmission now being widely reported [1], will likely result in an
increase in the logistic challenges and expense of undertaking such
trials in malaria-endemic areas, particularly with the growing
number of anti-malarial drugs in preclinical development.
Alternate approaches include testing for clearance of experimental
infection, induced either with sporozoites from mosquito bites [12]
or by injection of cryopreserved and thawed sporozoites
(ClinicalTrials.gov Identifier: NCT01086917) or blood-stage
parasites (BSP) within infected erythrocytes.
Induced blood stage infection was widely practiced following the
description of malariatherapy for syphilis, for which Julius
Wagner-Jauregg won the Nobel Prize in 1927. After the Second
World War, experimental studies using blood stage challenge were
undertaken for a number of purposes, including testing the efficacy
of blood stage schizonticides [13,14,15,16,17,18]. Indeed, this
approach was utilised in the successful development of halofan-
trine [19]. These studies were undertaken using a variety of strain
of P. falciparum, with varying chloroquine sensitivity [18]. However,
this approach was largely abandoned in the 1980’s due to ethical
and safety concerns.
Experimental blood stage infection was revived in the 1990’s as
a method for testing the efficacy of vaccines acting against the
blood stage of malaria infection [20]. Published experience with
the stored bank of blood-stage inocula that was prepared for these
studies now amounts to 40 malaria-naı¨ve volunteers in six clinical
studies [20,21,22,23,24]. These have demonstrated safety in the
volunteers, the reliability of this approach, and a more uniform
parasite growth rate after BSP challenge compared to mosquito
challenge [23]. Of note the strain of P. falciparum used is the
chloroquine-sensitive reference strain, 3D7, the same strain whose
genome has been sequenced. The safety for volunteers has been
further augmented by the availability of artemisinin antimalarials
that rapidly clear the parasitemia [25], and by the development of
rapid, sensitive and robust real-time PCR assays for quantification
of parasitemia [26]. We hypothesized that blood challenge would
provide a system for assessing the efficacy of new antimalarial drug
candidates for the treatment of P. falciparum malaria.
We have undertaken a randomised, unblinded, Phase IIa trial in
healthy, malaria-naı¨ve, male adults aiming to assess the feasibility
and safety of induced blood stage malaria challenge as a method
for assessment of efficacy of new drug candidates for the treatment
of P. falciparum infection. The study was designed as an enabling
study to inform subsequent trial design, and to identify endpoints
for assessing new candidate antimalarial drugs in development.
Two registered antimalarial drugs were selected as reference
treatments, one the relatively fast acting artemisinin combination
artemether-lumefantrine, and the other the relatively slow acting
drug combination atovaquone-proguanil [25]. Secondary objec-
tives included: i) confirming the parasite growth curves after
intravenous (I.V.) inoculation of healthy volunteers with P.
falciparum blood stage parasites, ii) establishing parasite clearance
profiles as measured by PCR after administration of the reference
drugs when administered at a target parasitemia of $1,000
parasites/mL, and iii) assessing the safety of this system of induced
blood stage malaria infection.
Materials and Methods
Ethics Statement
The study was approved by the Queensland Institute of Medical
Research Human Research Ethics Committee (QIMR-HREC)
and reviewed by the MMV Global Safety Board. The study was
conducted in accordance with the Declaration of Helsinki
principles for the conduct of clinical trials and the International
Committee of Harmonization Good Clinical Practice Guidelines
as recognized by the Australian Therapeutic Goods Administra-
tion (TGA) (www.tga.gov.au/docs/pdf/euguide/ich/ich13595.
pdf). The trial was conducted with regulatory oversight by the
TGA scheme (CTN # 2010/0042) and registered at the
ClinicalTrials.gov (NCT01055002). The protocol for this trial
and supporting CONSORT checklist are available as supporting
information; see Protocol S1, Checklist S1 and Protocol
Amendment S1.
The production of the parasite inoculum has been described
previously [20]. In brief, laboratory-reared Anopheles stephensi
mosquitoes were infected by membrane feeding on a blood meal
containing gametocytes with the chloroquine-sensitive P. falciparum
clone 3D7 derived from an isolate that had collected from an
airport worker in Amsterdam. Ten days after their last blood meal,
the mosquitoes were allowed to feed on a healthy male who had
no evidence of any blood borne virus infection. A 500 mL unit of
blood was taken from the volunteer six hours after he became ill
with the development of high fever, 13 days after the mosquito
bites. The blood was leucocyte depleted, mixed with the
cryopreservation agent Glycerolyte 57, aliquoted into 1-mL
cryovials and stored in liquid nitrogen at QIMR. Prior to use of
the aliquots, the volunteer was repeatedly evaluated for any
evidence of seroconversion to blood borne infections in order to
eliminate the risk of transferring infection to the recipient
volunteers. Up to date, 16 years after collection of the blood the
volunteer has remained healthy.
To prepare the inocula, an aliquot of the seed stock was thawed,
washed, and the inoculum prepared by diluting to the appropriate
dose and volume and dispensed aseptically into 2 mL syringes in
preparation for individual volunteer administration. The number
of viable parasites in the inoculum was verified in retrospect by
quantitative PCR as described below. It was planned that each
injected inoculum would contain ,120,000 erythrocytes, of which
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,5,400 were parasite-infected. As previous experience had
indicated that ,30% of blood stage parasites were viable [20],
the final dose was planned to be ,1,800 viable intraerythrocytic
parasites. Each challenge inoculum was dispensed into syringes
and stored in sealed plastic bags on ice until administered. The
time between thawing and injection was required to be
#60 minutes.
The inoculum size in terms of parasite genome equivalents and
parasitemia from clinical blood samples taken during the trial were
quantified by a Real-time Quantitative PCR assay as described
elsewhere [26]. In brief, whole blood samples were collected into
2 mL EDTA vacutainers (BD Australia) at 12 hour intervals from
Day 3, with additional samples collected at 6 hour intervals in the
48 hours following inoculation. Vacutainers were centrifuged for
5 minutes at 2,500 rpm; 500 ml of packed red cells was removed
and added to 500 ml of PBS and mixed. The sample was then
divided into two aliquots, one 500 mL aliquot was mixed with
400 ml of Qiagen AL Lysis buffer and DNA extracted using the
QIAamp DNA Mini kit following the manufacturer’s protocol. A
known concentration of equine herpes virus (EHV) was added to
each specimen to monitor the efficiency and reliability of the
extraction process. Nucleic acids were eluted in 100 ml of elution
buffer and stored at 280uC until PCR reactions were performed.
The PCR primers and cycling conditions were as previously
described [27]. Briefly, the reaction mix consisted of 12.5 ml
Quantitect Probe PCR Mix (Qiagen, Australia), 10 pmol of each
primer (PerFAL-Forward CTTTTGAGAGGTTTTGTTACT-
TTGAGTAA and PerFAL-Reverse TATTCCATGCTGTAG-
TATTCAAACACA), 4 pmol of probe (PerFAL-probe Fam-T-
GTTCATAACAGACGGGTAGTCATGATTGAGTTCA-BH-
Q1)and 5 ml of template in a 25 ml final reaction was performed in
a Rotorgene 3000 or 6000 (Qiagen, Australia) under the following
conditions: 15 min incubation at 95uC, followed by 45 cycles of
95uC for 15 s and 60uC for 1 min. PCR product quantitation was
undertaken using a standard curve prepared by serial dilutions of
control blood samples with parasitemia as determined by flow
cytometry [28]. Six standards were used on each run ranging from
6.46105 to 6.4 parasites per 500 mL of packed red blood cells
(approximating 1 mL of blood at a 50% haematocrit). Two
negative controls were included on each PCR run. Parasite
concentrations were calculated using the Qiagen, Rotorgene
software. Specimens were tested by PCR in duplicate and the
average parasite concentration for these two values is reported.
The limit of detection of the assay was determined to be 64
parasites per 500 mL of packed red blood cells, approximating a
count of 64 per mL, assuming a hematocrit of 45.
Participants were recruited at the trial site, Q-Pharm Pty Ltd,
Brisbane, QLD, Australia from January 2010 until June 2010. The
volunteers were randomized across the three cohorts 1:1 to the two
registered antimalarials artemether-lumefantrine (RiametTM, No-
vartis) and atovaquone-proguanil (MalaroneTM, GSK), both
administered according to their approved dosing schedules (4
tablets of Artemether 20 mg/Lumefantrine 120 mg, administered
at time 0, 12, 24, 36, 48, and 60 hours; 4 tablets of Atovaquone
250 mg/Proguanil100 mg administered at 0, 24, 48 hours).
Randomization was undertaken by the study pharmacist using
the SPSS software package to generate a treatment allocation
document. As this was a pilot trial and the principal outcome
variables to be analysed were the PCR-determined parasite
clearance kinetics, both the volunteers and the investigators were
unblinded. All PCR-based laboratory testing of the participant
blood samples was undertaken in a blinded fashion. It was
required that the interval between successive cohorts be at least 13
days to enable review by Safety Review Team at least 10 days
following completion of treatment in the previous cohort.
Following screening and informed consent, healthy, malaria naive
male volunteers were intravenously inoculated on Day 0 with
,5,400 P. falciparum-infected human erythrocytes. On an
outpatient basis, volunteers were monitored each morning and
evening from Day 3 to Day 7 after inoculation for adverse events
and the unexpected early onset of symptoms, signs or parasito-
logical evidence of malaria. If clinical or parasitological evidence of
malaria (either the identification of two or more malaria parasites
on a malaria thick film, platelet count less than 1006109/L, or the
onset of clinical features of malaria) or parasitemia of $1,000
parasites/mL as determined by PCR was detected before the
evening of Day 6, the protocol required that allocated treatment
begin at this time. On the evening of Day 6, volunteers were to be
admitted to the study unit and confined for safety monitoring and
antimalarial treatment. For the second and third cohorts,
continuation of outpatient monitoring was provided, if the growth
rate of the malaria parasites as determined by PCR was slower
than expected. For cohort one, antimalarial treatment was
designated to begin on the evening of Day 6 irrespective of
parasite count. For cohorts two and three, the timing of
administration of antimalarial therapy was modified such that it
was planned to begin on the evening after the first recording of a
parasitemia $1,000 parasites/mL. Following treatment, volun-
teers were followed as inpatients for at least 36 hours, (2 evenings)
to ensure tolerance of the therapy and clinical response, then, if
they were clinically well, they were on an outpatient basis for safety
and continued presence of malaria parasites via PCR and thick
blood film review. Adverse events were monitored either via
telephone, or within the clinical research unit and on outpatient
review after inoculation and antimalarial study drug administra-
tion.
A total of 36 healthy, malaria naı¨ve male volunteers, aged
between 18 to 45 years were recruited from a database of healthy
volunteers maintained by Q-Pharm, or by advertisement to
students of Queensland universities and the general community.
Screening medical histories and physical examinations were
performed after written informed consent had been obtained.
Details of the inclusion and exclusion criteria are available in
Protocol S1.
Vital signs (temperature, heart rate, blood pressure and
respiratory rate) were measured on Day 0 then at least daily from
Days 3–13 and blood was collected for safety purposes was
undertaken on a regular basis. Volunteers were monitored by a
medical investigator during the confinement period in the morning
and evening, and at the outpatients visit on Day 0, Days 3–7, Days
9–12, and at the follow up Day 28 visit. An experienced nurse was
in attendance at the study centre throughout the period of
inpatient confinement. For the duration of the study, a medical
Investigator was available within 30 minutes if required. Progress
of the trial and review of its safe conduct were overseen by a safety
review team including an independent medical expert.
Initial estimates of the required sample size were based on an
unpublished dataset of parasite clearance kinetics from a study
undertaken at The Radboud University Nijmegen Medical Centre
where volunteers had been treated with chloroquine. The group
size required to detect a 25% differences in parasite clearance rate
between two treatment arms was calculated to be 10 per treatment
group for a two sided test at the 5% level of significance with 80%
power. After the second cohort was completed, a second sample
size calculation was undertaken, and it was determined that a total
study size of 14 with seven volunteers in each arm would result in
the desired statistical power. The statistical analysis plan entailed
comparison of the two groups of drug treated volunteers using
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analysis of variance of the gradients estimated from the modelling
of parasite reduction rates [25]. A cohort effect was tested to look
for differences between cohorts, but was found to be unimportant.
Analysis entailed testing the effect size along with its 95%
confidence interval. The safety analysis plan entailed examining
the overall number and percentage of volunteers with at least one
AE or SAE in each cohort and over the entire study and included
the incidence, intensity, and relatedness to malaria infection or
antimalarial drug administered. Parasite clearance curves were
analysed by calculating a slope of log transformed parasitaemia
against time since treatment with antimalarials using linear
regression. The corresponding parasite reduction ratios (PRR)
were calculated from the mean slopes of the clearance curves for
the two treatment groups. This parameter reflects the fractional
reduction in parasitemia per asexual life cycle of 48 hours, and is
analagous to the killing rate induced by a specific drug [25]. A one
way ANOVA was used to compare the slopes between the
different treatments.
Results
Of 36 males screened as potential study volunteers, 19 were
deemed eligible and enrolled in three sequential cohorts (Figure 1).
Reasons for exclusion included the following: declined to
participate (n = 6), equivocal HIV antibody test (n = 1), elevated
Body Mass Index (n = 1), hemoglobin below 120 g/L (n = 1),
needle phobia (n = 1) and positive urine drug screen (n = 1); six
eligible volunteers were not required. The median age was 23
years (range 18–42 years); 17 of the enrolled volunteers were of
Caucasian background; two were Asian. The study was initially
designed to be conducted in two cohorts (n = 6 and n = 10). A
miscalculation in preparation of the inoculum in cohort one
resulted in the volunteers receiving a dose of parasites 5 fold lower
than stipulated. Although all became PCR positive, none reached
the target parasitemia of .1,000 parasites/mL before the
timepoint when antimalarial treatment was designated to
commence (Table S1). Following completion of the first cohort,
and safety review a number of changes were made to the protocol.
.The second cohort was reduced in size (n = 4); following successful
completion of study objectives in this, cohort, a third cohort was
enrolled with a planned size of ten volunteers. One subject in the
third cohort had a positive urine drug screen on the designated
day of inoculation and therefore was removed from the study
before receiving the inoculum. Thus the third cohort consisted of
nine volunteers.
No serious adverse events were recorded during the study. In
the first cohort of 6 volunteers who receivedt ,360 BSP, no
clinically significant symptoms or signs related to the inoculum or
drug treatments were noted (Table 1). One volunteer developed
transient neutrophilia (13.76109/L) on Day 9 (Table 2). This
resolved spontaneously. One volunteer in cohort one who was
randomised to artemether-lumefantrine withdrew from the study
on Day 5 due to a family emergency. He completed his
antimalarial treatment and returned to complete safety follow-up
on Day 28.
All of the volunteers in cohorts two and three who received a
higher dose of parasites of about 1,800 BSP, reached the target
parasitemia of $1,000 parasites/mL (see below). Symptoms
consistent with the early clinical features of malaria were
commonly observed (Table 1), with malaise, chills fever headache,
neck ache, mylagia and back ache being commonly reported.
These symptoms began to appear at peak parasitemia (from Day 7
onwards), were all of only mild to moderate severity, were of two
days duration or less, and resolved spontaneously, or after the
administration of paracetamol. One volunteer experienced fever
to over 39uC with rigors immediately prior to and just after the
commencement of antimalarial therapy. Two volunteers required
an additional 24 hours of observation beyond the protocol-
Figure 1. Participant flow.
doi:10.1371/journal.pone.0021914.g001
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mandated 36 hours due to persisting low grade fever. The
expected mild disturbances in haematologic and biochemical
parameters were observed. Moderate neutropenia (,2.06109/L),
and lymphocytopenia (,0.86109/L) were commonly observed
(n = 10 and n = 4 respectively; Table 2). These all occurred at the
time of peak parasitemia or soon after the commencement of
antimalarial chemotherapy. One volunteer developed transient
thrombocytopenia of three days duration, with a nadir platelet
count of 696109/L on Day 11. Transient rises in liver
transaminase levels above two times the upper limit of normal
occurred in two individuals (ALT 119 U/L on Day 14 in one
volunteer, and 117 U/L on Day 17 in the other); both had
normalised when retested on Day 28. One volunteer in cohort
three was found to have a mild idiopathic neutropenia that was
judged unrelated to the study. His screening haematology tests
were all in the normal range, but his neutrophil count on Day 0,
prior to inoculation was found on retrospect to be 1.606109/L.
His neutrophil count then rose into the normal range before falling
below 2.06109/L on Day 8. His neutrophil count remained below
2.06109/L until Day 44 when it was 1.646109/L. Although he
did not give a history suggestive of increased frequency or severity
of infections or other symptoms, he was referred for specialist
assessment by a hematologist, but his hematologic parameters had
returned to within the normal range by this time.
Thick blood films remained negative throughout the study for
all volunteers. Figure 2 shows the parasite growth and clearance
patterns for the 13 volunteers in cohorts 2 and 3, all of whom
reached the designated target parasitemia of .1,000 parasites/
mL. The median peak, pre-treatment parasitemia among these
volunteers was 2,926 parasites/mL, (range: 1,501–8,524). In the
artemether-lumefantrine treatment group parasites were cleared
between 1–2 days whereas in the atovaquone-proguanil treatment
group parasite clearance was 2.25–3 days. The clearance rates in
the artemether-lumefantrine and the atovaquone-proguanil treat-
ments groups were significantly different (p,0.01). The corre-
sponding parasite reduction ratios (PRR), calculated from the
mean slopes for the two treatment group were 759 (95% CI 120–
4786) and 17 (95% CI 7–40) respectively.
Table 1. Symptoms reported in the study volunteers.
Cohort 1 (n=6) Cohorts 2 and 3 (n=13)
Artemether/lumefantrine Atovaquone/proguanil Artemether/lumefantrine Atovaquone/proguanil
Malaise 1 1
Chills 1 2
Fever 2
Sweating 3
Facial flushing 1
Myalgia 2 2
Headache 2 4
Neck ache 1
Back pain 1
Nausea 1
Abdominal discomfort 1
Diarrhoea 1
Vivid dreams 1 1
Tongue ulcer 1
doi:10.1371/journal.pone.0021914.t001
Table 2. Abnormal laboratory values.
Cohort 1 (n=6) Cohorts 2 and 3 (n =13)
Artemether/lumefantrine Atovaquone/proguanil Artemether/lumefantrine Atovaquone/proguanil
Neutrophilia{ 1 1
Neutropenia{{ 4 6
Lymphocytopenia1 2 2
Thrombocytopenia11 1
Elevated ALT" 1 1
{(.11.06109/L).
{{(,2.06109/L).
1(,0.86109/L).
11(,1006109/L; nadir 696109/L on Day 11).
"(.26 normal; ,45 IU/mL).
doi:10.1371/journal.pone.0021914.t002
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Discussion
This study has demonstrated the feasibility and safety of induced
blood stage malaria infection as a method for assessment of
efficacy of antimalarials. When combined with a sensitive,
quantitative PCR assay for measurement of parasite growth and
clearance it is possible to gain robust clearance kinetic data from a
relatively small number of volunteers with submicroscopic level
infection. This all occurs largely before the volunteers develop
symptoms of malaria. Those volunteers who did develop early
clinical symptoms of malaria reported a rapid resolution of
symptoms within 48 hours of commencement of antimalarial
chemotherapy. The clinical and laboratory abnormalities observed
were mild, transient, and not different from those reported in
previous human volunteer studies where experimental malaria
infection has been undertaken, either by mosquito inoculation
[12,29,30,31,32], which now number over 1,000 volunteers
studied, or by blood stage inoculation [20,21,22,23,24].
The results of the analysis of the kinetics of parasite clearance
are in accordance with previous studies demonstrating the more
rapid activity of drugs of the artemisinin class over the relatively
slow-acting combination of atovaquone-proguanil. These results
indicate that this methodology provides an opportunity for
assessing the relative speed of clearance of parasites of new agents
compared with antimalarial agents with known activity.
While the confidence intervals of the clearance curves were
relatively wide in this study in which the cohort sizes were small
(six and seven, respectively), the shape of the curves following
administration of the antimalarials suggests that parasite clearance
begins immediately after administration of the artemisinin drug,
while there is a lag with the atovaquone-proguanil combination
(Figure 2), an observation in accordance with the hypothesis that
the artemisinins act throughout the parasite lifecycle, while the
other drug combination acts predominantly late in the parasite
lifecycle. It remains to be determined how the clearance kinetics as
determined by the sensitive PCR methodology observed at
submicroscopic parasitemia in largely asymptomatic volunteers
compare to those observed in symptomatic patients with clinical
malaria and significantly higher levels of parasitemia.
In many previous studies of the therapeutic efficacy of
antimalarial drugs, the clearance of parasitemia has been reported
as the parasite clearance time (PCT). This parameter is subject to a
number of confounding effects, including the height of parasitemia
at enrollment, the background immunity in the population [11],
the frequency of collection of blood films, and the expertise and
rigor in identifying parasites at low levels. Indeed, in most studies,
the threshold for detection of parasitemia in the study has not been
reported. A parameter that has been suggested as a more
appropriate measure of parasite clearance is the parasite reduction
ratio (PRR) [25]. This is the fractional reduction in parasitemia
over the parasite lifecycle (48 hours for P. falciparum). The PRR
values derived in our study were 759 for artemether-lumefantrine
and 17 for atovaquone-proguanil. As this value has not been
reported in most previous studies of these drug combinations, we
undertook a review of previous studies we were able to identify
where the starting parasitemia and parasite clearance times were
reported. We identified six studies where artemether-lumefantrine
was studied [33,34,35,36,37,38] and seven for atovaquone-
proguanil [39,40,41,42,43,44,45]. To calculate a PRR we
assumed that the threshold of detection of parasites on a thick
film was 20 parasites per microlitre. In the six studies where
sufficient data for artemether lumefantrine were available, the
PRR ranged from 217–39,705, while for the seven studies where
corresponding data for atovaquone-proguanil were available the
PRR ranged from 24–1,620 (Table S2). Thus the PRR value we
observed with artemether-lumefantrine is within the range of
previously reported values, while that for atovaquone/proguanil it
is slightly below the lowest. While there are a number of important
differences between these field studies and the experimental system
we used, including importantly the level of parasitemia, method of
quantification of parasitemia (blood film versus PCR) and the
background immunity of the study volunteers, the values derived
in this study are within the range reported in these studies.
Nevertheless, it will be useful to formally compare the results
obtained in this study with the situation that occurs in clinical
malaria by undertaking PCR-based study of parasite clearance
kinetics following treatment of symptomatic cases.
Figure 2. Growth and clearance of parasitemia in study subjects. The mean number of P. falciparum parasites before treatment (closed
circles; n = 13), and after treatment with artemether-lumefantrine (closes squares; n = 6) or with atovaquone-proguanil (closed diamonds; n = 7), as
determined by real-time polymerase-chain-reaction assay. The I bars denote standard errors.
doi:10.1371/journal.pone.0021914.g002
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Recently, there has been significantly more published experi-
ence with experimental malaria infections induced by mosquito
bite, for studies of immunity and vaccine testing [29,30,31,32] and
drug development [12], than by BSP challenge [20,21,22,23,24].
However, providing that the objective is to focus exclusively on
blood-stage effects, experimental infection with BSP offers some
significant advantages over infection by sporozoites. These include
the ability to tightly control the dose of parasites administered,
compared to mosquito inoculation where there is substantial
variability in the number of sporozoites inoculated [46,47]. Earlier
studies indicated that after the bite of 5 infected mosquitoes under
standard experimental conditions each mosquito injects ,5–10
sporozoites per bite [46]. However more recent studies indicate
that between 100 and 300 sporozoites are inoculated with each
bite [47,48]. As approximately 30,000 merozoites are released into
the bloodstream when a single infected hepatocyte ruptures, the
starting parasitemia is much lower and more tightly controlled in
our BSP experimental system. This provides an added margin of
safety and a longer opportunity to observe growth of parasitemia
using a sensitive PCR assay. A disadvantage of experimental
infection with BSP is the need to inoculate a small volume of
donor human blood. This risk has been minimized by exhaustive
testing of the donor, the fact that the donor remains healthy over
ten years after donating the malaria-infected blood unit, and by
the experience to date using this source material without any
infectious complications in the recipients. Further, no evidence has
accrued of alloimmunization to red cell antigens among recipients
of this material (data not shown). However, if the experimental
objective is to measure clearance of blood stage parasites, the
means of reaching the pre-treatment target parasitemia (by
inoculation of sporozoites or blood stage parasites) may be of
secondary importance.
Advantages of this system from a drug development perspective
include the ability to study an experimental antimalarial agent of
unknown efficacy under tightly controlled and monitored
conditions, and consequently the opportunity to easily and
simultaneously collect rich pharmacokinetic data in order to
understand the pharmacokinetic-pharmacodynamic relationship.
The reference P. falciparum strain used in this study is the best
studied strain of P. falciparum, with a well characterized drug
sensitivity profile. Overall, this provides a margin of safety above
that would not pertain if patients with symptomatic malaria were
studied in field settings. Thus this system would facilitate the
down-selection of ineffective new agents.
The falling prevalence of malaria in many parts of the world [1],
weak infrastructure and processes for ethical and regulatory review
resulting in unpredictable timelines, and the potentially large
number of novel antimalarials that may reach early efficacy
evaluation [6,7,8] pose specific problems for antimalarial drug
development. In this respect the availability of a new clinical
capacity to test experimental of antimalarials represents a
promising approach to screening novel agents and combinations.
The utility of this approach will be better defined once further
experience is gained with this system and its predictive in
symptomatic patients is defined.
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